ATIM-29. NRG BN002: SAFETY DATA FROM A PHASE I STUDY OF IPILIMUMAB (IPI), NIVOLUMAB (NIVO), AND THE COMBINATION FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Article
Gilbert, Mark, Zhang, Peixin, Sloan, Andrew et al. (2018). ATIM-29. NRG BN002: SAFETY DATA FROM A PHASE I STUDY OF IPILIMUMAB (IPI), NIVOLUMAB (NIVO), AND THE COMBINATION FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
. NEURO-ONCOLOGY, 20(suppl_6), vi7-vi7. 10.1093/neuonc/noy148.024
Gilbert, Mark, Zhang, Peixin, Sloan, Andrew et al. (2018). ATIM-29. NRG BN002: SAFETY DATA FROM A PHASE I STUDY OF IPILIMUMAB (IPI), NIVOLUMAB (NIVO), AND THE COMBINATION FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
. NEURO-ONCOLOGY, 20(suppl_6), vi7-vi7. 10.1093/neuonc/noy148.024